These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 7889535

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH.
    Cancer Res; 1999 Aug 15; 59(16):3998-4003. PubMed ID: 10463598
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D.
    Br J Cancer; 2001 Jun 15; 84(12):1671-6. PubMed ID: 11401322
    [Abstract] [Full Text] [Related]

  • 6. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ.
    Cancer Chemother Pharmacol; 1997 Jun 15; 40(4):277-84. PubMed ID: 9225945
    [Abstract] [Full Text] [Related]

  • 7. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
    Antoniw P, Springer CJ, Bagshawe KD, Searle F, Melton RG, Rogers GT, Burke PJ, Sherwood RF.
    Br J Cancer; 1990 Dec 15; 62(6):909-14. PubMed ID: 2257218
    [Abstract] [Full Text] [Related]

  • 8. Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
    Sharma SK, Boden JA, Springer CJ, Burke PJ, Bagshawe KD.
    Cell Biophys; 1994 Dec 15; 24-25():219-28. PubMed ID: 7736526
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study.
    Springer CJ, Poon GK, Sharma SK, Bagshawe KD.
    Cell Biophys; 1993 Dec 15; 22(1-3):9-26. PubMed ID: 7889545
    [Abstract] [Full Text] [Related]

  • 11. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH.
    Clin Cancer Res; 2000 Mar 15; 6(3):765-72. PubMed ID: 10741695
    [Abstract] [Full Text] [Related]

  • 12. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ.
    Cancer Chemother Pharmacol; 1997 Mar 15; 40(3):189-201. PubMed ID: 9219501
    [Abstract] [Full Text] [Related]

  • 13. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Spooner R, Davies L, Marais R, Springer CJ.
    J Med Chem; 1998 Dec 17; 41(26):5297-309. PubMed ID: 9857097
    [Abstract] [Full Text] [Related]

  • 14. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ, Antoniw P, Bagshawe KD, Wilman DE.
    Anticancer Drug Des; 1991 Nov 17; 6(5):467-79. PubMed ID: 1764165
    [Abstract] [Full Text] [Related]

  • 15. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
    Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ.
    Cancer Gene Ther; 2000 Oct 17; 7(10):1348-56. PubMed ID: 11059693
    [Abstract] [Full Text] [Related]

  • 16. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
    Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, Sherwood RF.
    Cancer; 1994 Feb 01; 73(3 Suppl):1114-20. PubMed ID: 8306255
    [Abstract] [Full Text] [Related]

  • 17. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC, Melton RG, Niculescu-Duvaz I.
    J Med Chem; 1995 Dec 22; 38(26):5051-65. PubMed ID: 8544182
    [Abstract] [Full Text] [Related]

  • 18. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
    Khan TH, Eno-Amooquaye EA, Searle F, Browne PJ, Osborn HM, Burke PJ.
    J Med Chem; 1999 Mar 25; 42(6):951-6. PubMed ID: 10090777
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.